These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31869745)

  • 1. Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients.
    Gallardo-Rincón D; Álvarez-Gómez RM; Montes-Servín E; Toledo-Leyva A; Montes-Servín E; Michel-Tello D; Alamilla-García G; Bahena-González A; Hernández-Nava E; Fragoso-Ontiveros V; Espinosa-Romero R; Cetina-Pérez L
    Transl Oncol; 2020 Feb; 13(2):212-220. PubMed ID: 31869745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
    Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation
    Gallardo-Rincón D; Montes-Servín E; Alamilla-García G; Montes-Servín E; Bahena-González A; Cetina-Pérez L; Morales Vásquez F; Cano-Blanco C; Coronel-Martínez J; González-Ibarra E; Espinosa-Romero R; María Alvarez-Gómez R; Pedroza-Torres A; Castro-Eguiluz D
    Front Genet; 2022; 13():863956. PubMed ID: 35734436
    [No Abstract]   [Full Text] [Related]  

  • 4. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
    Villarreal-Garza C; Weitzel JN; Llacuachaqui M; Sifuentes E; Magallanes-Hoyos MC; Gallardo L; Alvarez-Gómez RM; Herzog J; Castillo D; Royer R; Akbari M; Lara-Medina F; Herrera LA; Mohar A; Narod SA
    Breast Cancer Res Treat; 2015 Apr; 150(2):389-94. PubMed ID: 25716084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.
    Teixeira N; Mourits MJ; Vos JR; Kolk DM; Jansen L; Oosterwijk JC; Bock GH
    Maturitas; 2015 Oct; 82(2):197-202. PubMed ID: 26239500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
    BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
    Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
    J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
    Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
    Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
    Rybchenko LA; Poluben LO; Bychkova GM; Stephanovych GV; Klymenko SV
    Probl Radiac Med Radiobiol; 2019 Dec; 24():455-464. PubMed ID: 31841487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).
    Modugno F; Moslehi R; Ness RB; Nelson DB; Belle S; Kant JA; Wheeler JE; Wonderlick A; Fishman D; Karlan B; Risch H; Cramer DW; Dube MP; Narod SA
    Cancer Causes Control; 2003 Jun; 14(5):439-46. PubMed ID: 12946038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
    Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
    Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.